Literature DB >> 361068

Comparison of placebo and bromocriptine in the treatment of patients with normoprolactinaemic amenorrhoea.

P G Crosignani, E Reschini, G C Lombroso, M Arosio, M Peracchi.   

Abstract

Fourteen women with normoprolactinaemic amenorrhoea were treated with bromocriptine (2.5 mg twice daily) for a period ranging from 4 to 17 weeks, while a matched group fo 19 amenorrhoeic women were treated with a placebo (one tablet twice daily) for 4 to 12 weeks. About half of the patients in both groups had at least one episode of vaginal bleeding during treatment. There was no clear difference in the menstrual and ovulatory pattern between placebo and bromocriptine groups.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 361068     DOI: 10.1111/j.1471-0528.1978.tb15601.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  2 in total

1.  Prolactin response to thyrotropin-releasing hormone in normoprolactinemic patients with ovulatory dysfunction and its use for selection of candidates for bromocriptine therapy.

Authors:  E Steinberger; S Nader; L Rodriguez-Rigau; C Ayala; K Smith
Journal:  J Endocrinol Invest       Date:  1990-09       Impact factor: 4.256

Review 2.  Use of bromocriptine in hyperprolactinaemic anovulation and related disorders.

Authors:  S Franks
Journal:  Drugs       Date:  1979-05       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.